High affinity and selective EP4
= 3 nM). Exhibits >2500-fold selectivity for EP4
. Also selective over a range of other prostanoid receptors, ion channels, transporters and enzymes. Inhibits PGE2
-induced vasodilation of middle cerebral and meningeal arteries in vitro
, and carotid blood flow in vivo
. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
From virtual to clinical: The discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor.
Sutton et al.